Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Production & Manufacturing
Manufacturing
Return to: PBR Home | Production & Manufacturing | Manufacturing

Mylan, Pfizer settle epinephrine auto-injector patent litigation with Sanofi

PBR Staff Writer Published 17 February 2012

Mylan and Pfizer have agreed to settle their patent litigation with Sanofi-Aventis over pre-filled injections designed to treat severe allergic reactions.

Meridian Medical Technologies, a Pfizer subsidiary, has signed a settlement agreement with Intelliject and Sanofi that will resolve pending patent litigation related to Intelliject's NDA for its epinephrine auto-injector (e-cue).

Under the settlement agreement, Intelliject and Sanofi may launch e-cue no earlier than 15 November 2012, subject to receipt of final approval from the FDA.

Meridian manufactures e-cue and Mylan Specialty commercializes the product in the US.

Mylan CEO Heather Bresch said the EpiPen Auto-Injector will continue to be a market leader, given the proud, 20-year heritage of this important treatment for anaphylaxis.

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.